

## Aponvie<sup>™</sup> (aprepitant) – New drug approval

- On September 16, 2022, <u>Heron Therapeutics</u> announced the <u>FDA approval</u> of <u>Aponvie</u>
  (aprepitant) injectable emulsion, for the prevention of postoperative nausea and vomiting (PONV) in adults.
  - Aponvie has not been studied for the treatment of established nausea and vomiting.
- A different aprepitant injectable emulsion is available under the brand name <u>Cinvanti®</u> and approved in adults for the prevention of chemotherapy-induced nausea and vomiting.
- An oral formulation of aprepitant is available generically as a capsule as well as a branded oral suspension (<u>Emend®</u>).
  - The oral suspension and capsules are approved for prevention of chemotherapy-induced nausea and vomiting in patients 6 months of age and older and patients 12 years of age and older, respectively.
  - Generic versions of <u>aprepitant capsules</u> are also approved for the prevention of PONV in adults.
- The safety and efficacy of Aponvie have been established based on adequate and well-controlled studies of a single-dose of oral aprepitant in adults.
- Aponvie is contraindicated in patients:
  - With a history of hypersensitivity to aprepitant or any component of the product
  - Taking pimozide.
- Warnings and precautions for Aponvie include hypersensitivity reactions, clinically significant CYP3A4 drug interactions, decrease in International Normalized Ratio (INR) with concomitant warfarin, and risk of reduced efficacy of hormonal contraceptives.
- The most common adverse reactions (≥ 3%) with single-dose Aponvie use were constipation, fatigue, and headache. The most common adverse reactions (≥ 3%) with single-dose oral aprepitant use were constipation and hypotension.
- The recommended dose in adults of Aponvie is 32 mg administered as a 30 second intravenous injection prior to induction of anesthesia.
- Heron Therapeutics' launch plans for Aponvie are pending. Aponvie will be available as a 32 mg /4.4 mL single-dose vial.

## **Optum**

At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.